Detalles de la búsqueda
1.
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Cardiovasc Diabetol
; 18(1): 149, 2019 11 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31706300
2.
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.
Eur Heart J
; 39(5): 374-381, 2018 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29186504
3.
Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
Kidney Int
; 93(6): 1397-1408, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29526502
4.
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
Diabetes Obes Metab
; 20(10): 2389-2398, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29802688
5.
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
Diabetes Obes Metab
; 19(12): 1781-1792, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28905478
6.
Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.
J Alzheimers Dis
; 88(4): 1585-1603, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35811522
7.
Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics.
Antimicrob Agents Chemother
; 54(6): 2330-7, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20231396
8.
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab.
Eur J Prev Cardiol
; 27(15): 1663-1674, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32089006
9.
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
Am J Cardiol
; 121(8): 940-948, 2018 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29472008
10.
Whole-genome profiling helps to classify phyllodes tumours of the breast.
J Clin Pathol
; 69(12): 1081-1087, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27207013
11.
A Multi-Marker Genetic Association Test Based on the Rasch Model Applied to Alzheimer's Disease.
PLoS One
; 10(9): e0138223, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26379234
12.
A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.
Orphanet J Rare Dis
; 10: 74, 2015 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-26070802
13.
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Orphanet J Rare Dis
; 9: 201, 2014 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25491744
14.
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Orphanet J Rare Dis
; 9: 199, 2014 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-25519680
15.
Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Orphanet J Rare Dis
; 11(1): 92, 2016 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27387831
16.
EMA - A R package for Easy Microarray data analysis.
BMC Res Notes
; 3: 277, 2010 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-21047405
Resultados
1 -
16
de 16
1
Próxima >
>>